ArticleScientific reports2025
Characterizing heterogeneity in Alzheimer's disease progression: a semiparametric model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The progression of Alzheimer's disease (AD), a leading cause of dementia worldwide, is known for its variability and complexity, challenging the conventional methods of monitoring and predicting disease trajectories. This study introduces a semiparametric modeling approach to analyze longitudinal cognitive and imaging data. We studied two different outcome variables from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database: the Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS13) scores and ventricular volumes [Formula: see text]. Unlike traditional linear mixed effects models, semiparametric models do not assume a linear AD progression over time. Semiparametric models offer the advantage of capturing the non-linear features of AD progression, such as cognitive decline and neurodegeneration, represented by changes in ADAS13 scores and ventricular enlargement, respectively. By integrating regression splines and mixed modeling techniques, we provide a nuanced understanding of AD progression that captures the heterogeneity of disease trajectories. Our analysis reveals variations in the timing and degree of cognitive decline and neurodegeneration among AD patients, underlining the need for personalized approaches for monitoring and managing AD. This study's findings contribute to the modeling of AD progression and offer potential implications for interventions and prognostic assessments in clinical and research settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.